Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA

Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA

Abstract PARP inhibitors (PARPi), recently introduced for treating metastatic castration-resistant prostate cancer (mCRPC), have heightened interest in molecular profiling for pathogenic aberrations in homologous recombination DNA repair (HRR) genes in all mCRPC patients. Liquid biopsy offers a viab...

Full description

Saved in:
Bibliographic Details
Main Authors: Alessandra Virga, Milena Urbini, Maurizio Polano, Elisabetta Petracci, Gianluca Tedaldi, Giorgia Gurioli, Giorgia Marisi, Davide Angeli, Andrea Ambrosini-Spaltro, Giovanni De Luca, Ilaria Cangini, Valentina Zampiga, Giovanna Cenacchi, Giuseppe Toffoli, Chiara Casadei, Maria Concetta Cursano, Vincenza Conteduca, Ugo De Giorgi, Paola Ulivi
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Prostate cancer
Liquid biopsy
PARP inhibitors
Low-coverage WGS
Online Access:https://doi.org/10.1038/s41598-025-05384-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-05384-4

Similar Items